Short-term effects of obestatin on hexose uptake and triacylglycerol breakdown in human subcutaneous adipocytes

Table 1 Clinical parameters of the study group and characteristics of adipocyte preparations

Clinical characteristics of SCAT donors
BMI of subjects, kg/m2	26.1 ± 0.7
Age, yr	40 ± 3
Biochemical features of adipocyte preparations
Cell lipid content/lipolysis assay, mg (n)	14.1 ± 1.3 (7)
Cell lipid content/glucose uptake assay, mg (n)	15.9 ± 1.3 (10)
Lipolytic responsiveness (fold increase over basal glycerol release, n = 7)
Basal	1.00 ± 0.17
Isoprenaline 10 μmol/L	5.14 ± 0.67b
Human atrial natriuretic peptide 1 μmol/L	5.16 ± 0.44b
Glucose transport capacity (fold increase over basal 2DG uptake, n = 10)
Basal	1.00 ± 0.13
Insulin 100 nmol/L	3.14 ± 0.28b
Hydrogen peroxide 1 mmol/L	1.72 ± 0.27a

Adipocytes were isolated by liberase digestion from pieces of SCAT obtained from a total of 13 women then incubated for lipolysis and/or glucose uptake assays for the number of individual preparations indicated in parenthesis. Different from respective basal values at:

^aP < 0.05;

^bP < 0.001. SCAT: Subcutaneous adipose tissue.

Table 2 Influence of obestatin on antilipolytic and glucose transport activities of human subcutaneous adipocytes

	n	Treatment	Control	Obestatin 1 nmol/L	Obestatin 10 nmol/L	Obestatin 100 nmol/L	UK14304 1 μmol/L
Lipolysis, µmol glycerol/ 100 mg lipid/90 min	3	Isoprenaline	0.64 ± 0.10	0.61 ± 0.09	0.62 ± 0.10	0.62 ± 0.10	0.29 ± 0.04a
Glucose transport, nmol 2-DG/100 mg lipids/10 min	10	Insulin	0.46 ± 0.14	0.45 ± 0.09	0.45 ± 0.09	0.43 ± 0.09	ND

Fat cells were incubated with a submaximal dose of the reference activator of lipolysis (isoprenaline 100 nmol/L), or glucose transport (insulin 5 nmol/L) alone (control) or with the indicated agents. Mean ± SEM. Different from corresponding control at:

^aP < 0.05. ND: Not determined.